Cargando…

Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs

Coronary transient receptor potential canonical (TRPC) channel expression is elevated in metabolic syndrome (MetS). However, differential contribution of TRPCs to coronary pathology in MetS is not fully elucidated. We investigated the roles of TRPC1 and TRPC6 isoforms in coronary arteries of MetS pi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wennan, Chen, Xingjuan, Riley, Ashley M., Hiett, S. Christopher, Temm, Constance J., Beli, Eleni, Long, Xin, Chakraborty, Saikat, Alloosh, Mouhamad, White, Fletcher A., Grant, Maria B., Sturek, Michael, Obukhov, Alexander G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534204/
https://www.ncbi.nlm.nih.gov/pubmed/28756533
http://dx.doi.org/10.1007/s00395-017-0643-0
_version_ 1783253737389686784
author Li, Wennan
Chen, Xingjuan
Riley, Ashley M.
Hiett, S. Christopher
Temm, Constance J.
Beli, Eleni
Long, Xin
Chakraborty, Saikat
Alloosh, Mouhamad
White, Fletcher A.
Grant, Maria B.
Sturek, Michael
Obukhov, Alexander G.
author_facet Li, Wennan
Chen, Xingjuan
Riley, Ashley M.
Hiett, S. Christopher
Temm, Constance J.
Beli, Eleni
Long, Xin
Chakraborty, Saikat
Alloosh, Mouhamad
White, Fletcher A.
Grant, Maria B.
Sturek, Michael
Obukhov, Alexander G.
author_sort Li, Wennan
collection PubMed
description Coronary transient receptor potential canonical (TRPC) channel expression is elevated in metabolic syndrome (MetS). However, differential contribution of TRPCs to coronary pathology in MetS is not fully elucidated. We investigated the roles of TRPC1 and TRPC6 isoforms in coronary arteries of MetS pigs and determined whether long-term treatment with a mineralocorticoid receptor inhibitor, spironolactone, attenuates coronary TRPC expression and associated dysfunctions. MetS coronary arteries exhibited significant atherosclerosis, endothelial dysfunction, and increased histamine-induced contractions. Immunohistochemical studies revealed that TRPC6 immunostaining was significantly greater in the medial layer of MetS pig coronary arteries compared to that in Lean pigs, whereas little TRPC6 immunostaining was found in atheromas. Conversely, TRPC1 immunostaining was weak in the medial layer but strong in MetS atheromas, where it was predominantly localized to macrophages. Spironolactone treatment significantly decreased coronary TRPC expression and dysfunctions in MetS pigs. In vivo targeted delivery of the dominant-negative (DN)-TRPC6 cDNA to the coronary wall reduced histamine-induced calcium transients in the MetS coronary artery medial layer, implying a role for TRPC6 in mediating calcium influx in MetS coronary smooth muscles. Monocyte adhesion was increased in Lean pig coronary arteries cultured in the presence of aldosterone; and spironolactone antagonized this effect, suggesting that coronary mineralocorticoid receptor activation may regulate macrophage infiltration. TRPC1 expression in atheroma macrophages was associated with advanced atherosclerosis, whereas medial TRPC6 upregulation correlated with increased histamine-induced calcium transients and coronary contractility. We propose that long-term spironolactone treatment may be a therapeutic strategy to decrease TRPC expression and coronary pathology associated with MetS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00395-017-0643-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5534204
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-55342042017-08-14 Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs Li, Wennan Chen, Xingjuan Riley, Ashley M. Hiett, S. Christopher Temm, Constance J. Beli, Eleni Long, Xin Chakraborty, Saikat Alloosh, Mouhamad White, Fletcher A. Grant, Maria B. Sturek, Michael Obukhov, Alexander G. Basic Res Cardiol Original Contribution Coronary transient receptor potential canonical (TRPC) channel expression is elevated in metabolic syndrome (MetS). However, differential contribution of TRPCs to coronary pathology in MetS is not fully elucidated. We investigated the roles of TRPC1 and TRPC6 isoforms in coronary arteries of MetS pigs and determined whether long-term treatment with a mineralocorticoid receptor inhibitor, spironolactone, attenuates coronary TRPC expression and associated dysfunctions. MetS coronary arteries exhibited significant atherosclerosis, endothelial dysfunction, and increased histamine-induced contractions. Immunohistochemical studies revealed that TRPC6 immunostaining was significantly greater in the medial layer of MetS pig coronary arteries compared to that in Lean pigs, whereas little TRPC6 immunostaining was found in atheromas. Conversely, TRPC1 immunostaining was weak in the medial layer but strong in MetS atheromas, where it was predominantly localized to macrophages. Spironolactone treatment significantly decreased coronary TRPC expression and dysfunctions in MetS pigs. In vivo targeted delivery of the dominant-negative (DN)-TRPC6 cDNA to the coronary wall reduced histamine-induced calcium transients in the MetS coronary artery medial layer, implying a role for TRPC6 in mediating calcium influx in MetS coronary smooth muscles. Monocyte adhesion was increased in Lean pig coronary arteries cultured in the presence of aldosterone; and spironolactone antagonized this effect, suggesting that coronary mineralocorticoid receptor activation may regulate macrophage infiltration. TRPC1 expression in atheroma macrophages was associated with advanced atherosclerosis, whereas medial TRPC6 upregulation correlated with increased histamine-induced calcium transients and coronary contractility. We propose that long-term spironolactone treatment may be a therapeutic strategy to decrease TRPC expression and coronary pathology associated with MetS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00395-017-0643-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-07-29 2017 /pmc/articles/PMC5534204/ /pubmed/28756533 http://dx.doi.org/10.1007/s00395-017-0643-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Contribution
Li, Wennan
Chen, Xingjuan
Riley, Ashley M.
Hiett, S. Christopher
Temm, Constance J.
Beli, Eleni
Long, Xin
Chakraborty, Saikat
Alloosh, Mouhamad
White, Fletcher A.
Grant, Maria B.
Sturek, Michael
Obukhov, Alexander G.
Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs
title Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs
title_full Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs
title_fullStr Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs
title_full_unstemmed Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs
title_short Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs
title_sort long-term spironolactone treatment reduces coronary trpc expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs
topic Original Contribution
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534204/
https://www.ncbi.nlm.nih.gov/pubmed/28756533
http://dx.doi.org/10.1007/s00395-017-0643-0
work_keys_str_mv AT liwennan longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT chenxingjuan longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT rileyashleym longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT hiettschristopher longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT temmconstancej longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT belieleni longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT longxin longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT chakrabortysaikat longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT allooshmouhamad longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT whitefletchera longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT grantmariab longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT sturekmichael longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs
AT obukhovalexanderg longtermspironolactonetreatmentreducescoronarytrpcexpressionvasoconstrictionandatherosclerosisinmetabolicsyndromepigs